Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189644
Status:
UNKNOWN
Last Update Posted:
2005-09-19
First Post:
2005-09-12
Brief Title:
6 FEC 100 Vs 4 FEC 100 Followed by 4 Taxol in N Breast Cancer
Sponsor:
Association Européenne de Recherche en Oncologie
Organization:
Association Européenne de Recherche en Oncologie
Study Overview
Official Title:
None
Status:
UNKNOWN
Status Verified Date:
2005-09
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of this randomized trial is to compare 6 FEC100 to 4 FEC100 4 Taxol in patients with resected node positive breast cancer Main endpoint is disease free survival Secondary endpoints are overall survival time to local recurrence time to distant metastases and tolerance A total of 840 patients have been included in the trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None